Novo Nordisk A/S (NYSE:NVO) Shares Sold by Harvest Fund Management Co. Ltd

Harvest Fund Management Co. Ltd cut its position in shares of Novo Nordisk A/S (NYSE:NVO) by 96.8% in the 3rd quarter, HoldingsChannel.com reports. The firm owned 675 shares of the company’s stock after selling 20,128 shares during the period. Harvest Fund Management Co. Ltd’s holdings in Novo Nordisk A/S were worth $80,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in NVO. Tidal Investments LLC lifted its position in shares of Novo Nordisk A/S by 13.1% in the first quarter. Tidal Investments LLC now owns 4,146 shares of the company’s stock valued at $532,000 after acquiring an additional 481 shares in the last quarter. Citizens Financial Group Inc. RI grew its holdings in shares of Novo Nordisk A/S by 1.5% during the first quarter. Citizens Financial Group Inc. RI now owns 13,904 shares of the company’s stock worth $1,785,000 after buying an additional 201 shares in the last quarter. Strategic Wealth Partners Ltd. raised its position in shares of Novo Nordisk A/S by 13.5% in the first quarter. Strategic Wealth Partners Ltd. now owns 2,339 shares of the company’s stock valued at $300,000 after buying an additional 278 shares during the last quarter. First City Capital Management Inc. acquired a new position in shares of Novo Nordisk A/S in the 1st quarter valued at $207,000. Finally, Burney Co. purchased a new stake in shares of Novo Nordisk A/S during the 1st quarter valued at $243,000. Hedge funds and other institutional investors own 11.54% of the company’s stock.

Wall Street Analyst Weigh In

NVO has been the topic of several research reports. Cantor Fitzgerald reaffirmed an “overweight” rating and issued a $160.00 target price on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. BMO Capital Markets cut their price objective on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating on the stock in a report on Thursday, October 17th. Finally, StockNews.com upgraded Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a report on Friday, November 1st. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Buy” and an average price target of $144.50.

Novo Nordisk A/S Trading Down 0.0 %

NYSE:NVO opened at $106.12 on Thursday. Novo Nordisk A/S has a 12 month low of $94.73 and a 12 month high of $148.15. The business’s 50-day moving average is $113.80 and its two-hundred day moving average is $128.33. The company has a debt-to-equity ratio of 0.43, a current ratio of 0.94 and a quick ratio of 0.75. The firm has a market capitalization of $476.22 billion, a PE ratio of 34.34, a price-to-earnings-growth ratio of 1.35 and a beta of 0.42.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.